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Introduction
Abnormal liver function is usually found in thyrotoxi-
cosis. Hyperthyroidism may cause an elevation of serum
hepatic enzymes and bilirubin levels1. Hepatotoxicity
is also one major side effect of antithyroid agents, includ-
ing carbimazole, methimazole and propylthiouracil.
Cholestasis is an adverse effect of methimazole and
carbimazole2. We report an elderly male patient with
thyrotoxicosis who developed cholestasis following
treatment with methimazole.
Case Report
A 69-year-old male, a farmer, was admitted to our
institution because of fever and chills lasting for 1 day.
He had a history of thyrotoxicosis and received subtotal
thyroidectomy about 30 years previously. No recurrence
of thyrotoxicosis was noted after the management. In
6 months, his body weight decreased from 58kg to 39kg.
Poor appetite, nausea and weakness were also present.
He also had dyspnea on exertion and hand tremor.
Poor sleep, loose stool and heat intolerance were also
found. No other symptoms were noted. He had not
had any recent change in his medication, and he de-
nied chronic viral hepatitis, alcohol consumption, blood
transfusion, recent travel or animal contact. He had
no family history of thyroid or liver disease.
He visited our outpatient department because of
shortness of breath, malaise, and body weight loss. He
had a free thyroxine of 9.07 ng/dL (reference range,
0.80–2.00 ng/dL) and thyroid-stimulating hormone of
0.05 μIU/mL (reference range, 0.25–4.00 μIU/mL). Mild
elevation of serum alanine aminotransferase (ALT) at
42 IU/L (reference range, 15–41 IU/L) and serum alkaline
phosphatases at 135 IU/L (reference range, 38–126 IU/L)
was found, but a normal concentration of serum aspar-
tate aminotransferase (AST) at 40 IU/L (reference range,
14–40 IU/L) was noted. Abdominal ultrasound revealed
liver calcification and a gallbladder polyp.
He was thin and chronically ill-looking. His body
height of 163 cm and body weight of 39 kg were noted.
Heart rate was 87 beats/min. Blood pressure was 124/
87 mmHg. There was no exophthalmos. The thyroid
was palpable. Physical examination did not reveal any
icteric sclera, ascites, hepatomegaly, splenomegaly or
other signs related to chronic liver disease. No other
positive signs were found by physical examination.
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Thyrotoxicosis due to Graves disease was diagnosed.
During the outpatient department visit, methimazole
30 mg daily in divided doses was prescribed as well as
β-adrenergic blockade with propranolol 10 mg three
times a day.
Four days later, he presented at our emergency
department with fever and fatigue. He exhibited a
body temperature of 39.2°C, a pulse rate of 87/min
and a respiratory rate of 20/min. The blood pressure
was 132/63 mmHg. Icteric sclera accompanied by acute
ill demeanor was found. Breathing sounds were clear.
No tenderness, Murphy’s sign, knocking pain or other
related signs were found. Laboratory data revealed
leukocytosis with leukocytes at 20,300/μL and left shift
in differential count. Elevated serum AST (134 IU/L)
and ALT (124 IU/L) and total bilirubin (5.5 mg/dL) were
found. No pyuria was present in the urinalysis. The
chest X-ray showed emphysema changes but no con-
solidation or filtration as in pneumonia. Abdominal
ultrasound found contracted gallbladder with gallblad-
der wall thickening without dilatation of the common
bile duct. He was hospitalized with the suspicion of acute
cholecystitis. Thyroid ultrasound revealed multinodu-
lar goiter and heterogeneous parenchyma, suggestive
of autoimmune thyroid disorder.
After admission, empiric antibiotic therapy with
flomoxef (3 g daily) in divided doses was started.
Methimazole (20 mg daily) and propranolol (30 mg
daily) were maintained because of his thyrotoxicosis.
Blood culture isolated Escherichia coli with sensitivity
to cephalosporin. Duodenal ulcer and esophageal
ulcer with anemia were also found after admission.
With the initiation of antibiotic therapy, his fever
and leukocytosis improved. No black stool or tarry
stool was kept. At that time, the total bilirubin was
4.1mg/dL, with an AST of 51 IU/L and an ALT of 61 IU/L.
Antinuclear factor and anti-double-stranded DNA were
investigated for the suspicion of autoimmune hepatitis,
but no positive finding was found.
Cholestasis and acute cholecystitis caused by methi-
mazole were suspected. So methimazole was held and
Lugol’s solution administered. Then, the patient under-
went subtotal thyroidectomy. Three days after the sur-
gery, the serum total bilirubin level was lowered to
1.4 mg/dL with an AST of 37 IU/L and an ALT of 47 IU/L.
One month later, the total bilirubin normalized to
1.1 mg/dL, while AST and ALT remained at the same
levels. Levothyroxine (50 μg) was supplied for his post-
surgical hypothyroidism.
Discussion
Hepatic dysfunctions, including elevated serum AST and
ALT levels, hepatitis and cholestasis, are usually noted
in patients with hyperthyroidism. This relationship was
reported more than 100 years ago3. Hyperthyroidism
causes hepatic dysfunction or cholestasis. Abnormal
liver function tests occur in 15–76% of the cases4. The
hepatic dysfunction can also be secondary to other
complications of hyperthyroidism4,5. With medication,
the antithyroid agents have an adverse effect on hepatic
dysfunction.
The liver plays a major role in the metabolism 
of thyroxine6. Hyperthyroidism causes liver damage
directly. Autopsies in patients with hyperthyroidism
demonstrate hepatic inflammation, fibrosis, and cen-
trilobular necrosis7. Organ oxygen consumption but not
blood flow augments with the increase of the metabolic
rate. The arteriovenous oxygen difference across the
splanchnic bed increases, and hypoxia causes hepatic
differences. A reduction in heart rate and cardiac 
output by β-adrenergic blockade may encourage the
progress1,4,8.
Autoimmune liver disease is related to autoim-
mune thyroid disease, which causes most cases of
hyperthyroidism. Tests for antinuclear factor and anti-
double-stranded DNA, and even liver biopsy, can be
performed to differentiate autoimmune hepatitis from
other hepatic injury conditions in hyperthyroidism8,9.
Hashimoto thyroiditis is thought to be related to primary
biliary cirrhosis8.
Cholestasis may occur in patients with hyperthy-
roidism. Bile transport is interfered with due to the
increase of hepatic oxygen consumption but without
an increase of hepatic blood flow thus lowering the
oxygen tension in the centrilobular zone. Thyroxine also
can cause cholestasis directly4. Jaundice from congestive
liver may be secondary to thyrotoxic heart failure10.
Antithyroid agents, including methimazole and
propylthiouracil, have an adverse effect on hepatic
dysfunction. The injury is likely to be mediated by
immune mechanisms. The estimated incidence of
antithyroid agents associated with hepatotoxicity is
about 0.5%11. The estimated frequency of immunoal-
lergic hepatitis is 0.1–0.2%. Immunoallergic hepatitis
is seen exclusively in patients treated with propylth-
iouracil. A transient increase in AST and ALT levels is
observed in 30% of patients taking propylthiouracil12.
It happens at all ages and more often in females4. 
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The propylthiouracil-induced hepatic injury is usually
subclinical and difficult to diagnose. It can, however,
rarely cause submassive hepatic necrosis and hepatic
failure. Cholestasis is a rare pattern of hepatotoxicity
associated with the antithyroid agents and has been
reported exclusively with Tapazole (methimazole)12.
Hepatotoxicity by Tapazole is thought to be related to
cell-mediated immunity4.
In the present case, serum AST and ALT levels were
normal prior to medical management. Hyperbiliru-
binemia and elevated serum AST and ALT levels
appeared after only a 4-day course of methimazole
therapy. These abnormalities persisted with the remis-
sion of leukocytosis due to acute cholecystitis and sub-
sided after the withdrawal of methimazole. The timing
suggests a causal association between methimazole and
hepatic dysfunction. Acute cholecystitis had not been
previously reported as an adverse effect of antithyroid
agents, but it can be secondary to cholestasis.
Hepatic dysfunction is usual in patients with hyper-
thyroidism. It may be due to the disease or the medica-
tion. Hepatic test function should be closely monitored
in patients with hyperthyroidism. The possible etiologies
of hepatic dysfunction in patients with hyperthyroidism
should be kept in mind to adjust the management of
hyperthyroidism.
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